GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tribute Pharmaceuticals Canada Inc (OTCPK:TBUFF) » Definitions » Dividend-Payout-to-FFO

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Dividend-Payout-to-FFO


View and export this data going back to . Start your Free Trial

What is Tribute Pharmaceuticals Canada Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

Tribute Pharmaceuticals Canada (Tribute Pharmaceuticals Canada) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tribute Pharmaceuticals Canada Inc (OTCPK:TBUFF) » Definitions » Dividend-Payout-to-FFO
Comparable Companies
CURR HAPP ASX:EXL XKRX:004310 TSX:CORV XKRX:006620 HKSE:06896 XKRX:054670 XKRX:003120 XKRX:041910 BNIGF XCNQ:VREO TSX:TRST ORSE:OLF1R XKRX:000520 XKRX:063160 ROCO:6539 XCNQ:FONE PHS:EURO STC:TRA
Traded in Other Exchanges
N/A
Address
Website
http://www.stellarpharma.com
Tribute Pharmaceuticals Canada Inc was incorporated under the Business Corporations Act (Ontario) on November 14, 1994. The Company is a specialty pharmaceutical company. It conducts acquisition, licensing, development and promotion of healthcare products in Canada. It sells Uracyst and NeoVisc internationally through a number of strategic partnerships. The Company's portfolio of assets includes nine product lines, eight of which are on the market in Canada, including: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, Collatamp G, and MycoVa. The Company markets its products in Canada through its own sales force and currently has licensing agreements for the distribution of select products in over 20 countries, and continues to expand this footprint. It faces product competition from companies marketing competing pharmaceutical products and medical devices in Canada. The Company's operations are or may be subject to various federal, provincial, state and local laws, regulations and recommendations relating to the marketing of products and relationships with treating physicians, data protection, safe working conditions, laboratory and manufacturing practices, the export of products to certain countries and the purchase, storage, movement, use and disposal of hazardous or potentially hazardous substances.
Executives
John M Gregory director, 10 percent owner
Sj Strategic Investments Llc 10 percent owner
Joan P Gregory other: Member 340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
James M Gregory other: Member 340 EDGEMONT AVE., SUITE 500, BRISTOL TN 37620
Susan Gregory other: Member 340 MARTIN LUTHER KING, JR. BLVD, SUITE 200, BRISTOL TN 37620